ASTRAZEN

ASTRAZENECA PHARMA INDIA

Mid Cap BSE: 506820 NSE: ASTRAZEN
₹3055.05
-14.7 (-0.48%)
As on 16 August, 2022 | 22:51

Astrazeneca Pharma India Share Price

Astrazeneca Pharma India Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Astrazeneca Pharma India Share Returns

  • Over 1 Month 2.74%
  • Over 3 Month 21.61%
  • Over 6 Month 12.58%
  • Over 1 Year -3.58%

Astrazeneca Pharma India Key Statistics

P/E Ratio 106.8
PEG Ratio -6.8
Market Cap Cr 7,638
Price to Book Ratio 14.9
EPS 23.8
Dividend 0.3
Relative Strength Index 53.14
Money Flow Index 65.17
MACD Signal 55.85
Average True Range 80.82

Astrazeneca Pharma India Investment Rating

  • Master Rating:
  • Astrazeneca Pharma India has an operating revenue of Rs. 862.53 Cr. on a trailing 12-month basis. An annual revenue de-growth of -1% needs improvement, Pre-tax margin of 10% is healthy, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 6% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 90 which is a GREAT score indicating consistency in earnings, a RS Rating of 61 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 107 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

AstraZeneca Pharma India Financials
  • Indicator
  • Jun 2022
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 232
  • 232
  • 201
  • 198
  • 175
  • 210
  • Operating Expenses Qtr Cr
  • 204
  • 194
  • 186
  • 180
  • 160
  • 170
  • Operating Profit Qtr Cr
  • 28
  • 38
  • 15
  • 18
  • 16
  • 40
  • Depreciation Qtr Cr
  • 5
  • 4
  • 4
  • 4
  • 5
  • 6
  • Interest Qtr Cr
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • Tax Qtr Cr
  • 7
  • 9
  • 5
  • 4
  • 3
  • 10
  • Net Profit Qtr Cr
  • 20
  • 28
  • 11
  • 12
  • 10
  • 27

Astrazeneca Pharma India Technicals

EMA & SMA

Current Price
3063.
-6.75 (-0.22%)
  • Bullish Moving Average
  • ___
  • 10
  • Bearish Moving Average
  • ___
  • 6
  • 20 Day
  • 3058.12
  • 50 Day
  • 2964.74
  • 100 Day
  • 2905.61
  • 200 Day
  • 2874.79
  • 20 Day
  • 3072.01
  • 50 Day
  • 2940.55
  • 100 Day
  • 2825.72
  • 200 Day
  • 2873.15

Astrazeneca Pharma India Resistance and Support

PIVOT
₹3079.97
Resistance
  • First Resistance
  • 3112.94
  • Second Resistance
  • 3156.12
  • Third Resistance
  • 3189.09
Support
  • First Resistance
  • 3036.79
  • Second Resistance
  • 3003.82
  • Third Resistance
  • 2960.64
  • RSI
  • 53.14
  • MFI
  • 65.17
  • MACD Single Line
  • 55.85
  • MACD
  • 46.34

Astrazeneca Pharma India Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 6,294
  • 435,230
  • 69.15
  • Week
  • 7,491
  • 398,808
  • 53.24
  • 1 Month
  • 12,984
  • 681,668
  • 52.5
  • 6 Month
  • 15,926
  • 702,658
  • 44.12

Astrazeneca Pharma India Result Highlights

AstraZeneca Pharma India Synopsis

NSE-Medical-Diversified

Astrazeneca Pharma I is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 805.60 Cr. and Equity Capital is Rs. 5.00 Cr. for the Year ended 31/03/2022. AstraZeneca Pharma India Ltd. is a Public Limited Listed company incorporated on 11/07/1979 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24231KA1979PLC003563 and registration number is 003563.
  • Market Cap
  • 7,657
  • Sales
  • 863
  • Shares in Float
  • 0.63
  • No of funds
  • 80
  • Yield
  • 0.33
  • Book Value
  • 14.93
  • U/D Vol ratio
  • 2
  • LTDebt / Equity
  • Alpha
  • -0.02
  • Beta
  • 0.46

AstraZeneca Pharma India

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 75%
  • 75%
  • 75%
  • Mutual Funds
  • 1.07%
  • 0.99%
  • 0.97%
  • Insurance Companies
  • 0.03%
  • 0.03%
  • 0.03%
  • Foreign Portfolio Investors
  • 2.48%
  • 2.38%
  • 2.38%
  • Financial Institutions/ Banks
  • Individual Investors
  • 18.63%
  • 19.06%
  • 19.44%
  • Others
  • 2.79%
  • 2.54%
  • 2.18%

AstraZeneca Pharma India Management

  • Name
  • Designation
  • Mr. Narayan K Seshadri
  • Chairman & Ind.Director
  • Mr. Gagandeep Singh Bedi
  • Executive Director
  • Mr. Rajesh Marwaha
  • Executive Director
  • Mr. Ankush Nandra
  • Non Executive Director
  • Ms. Weiying Sarah Wang
  • Non Executive Director
  • Ms. Revathy Ashok
  • Independent Director
  • Ms. Shilpa Shidhar Divekar
  • Independent Director

Astrazeneca Pharma India Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Astrazeneca Pharma India Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-08-08
  • Quarterly Results
  • 2022-05-26
  • Audited Results & Final Dividend
  • 2022-02-08
  • Quarterly Results
  • 2021-11-09
  • Quarterly Results
  • 2021-08-09
  • Quarterly Results & Interim Dividend
  • Date
  • Purpose
  • Remarks
  • 2022-07-08
  • FINAL
  • Rs.8.00 per share(400%)Final Dividend
  • 2021-08-20
  • INTERIM
  • Rs.2.00 per share(100%)Interim Dividend

AstraZeneca Pharma India MF Shareholding

  • Name
  • Amount(cr)
  • Nippon India Small Cap Fund - Growth
  • 20363
  • ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
  • 2503
  • Nippon India Nifty Smallcap 250 Index Fund Reg Gr
  • 400
  • Motilal Oswal Nifty 500 Fund Regular Growth
  • 327
  • Motilal Oswal Nifty Smallcap 250 Index Fund Regular Growth
  • 274

AstraZeneca Pharma India FAQs

What is Share Price of AstraZeneca Pharma India ?

AstraZeneca Pharma India share price is ₹3055 As on 16 August, 2022 | 22:37

What is the Market Cap of AstraZeneca Pharma India ?

The Market Cap of AstraZeneca Pharma India is ₹7637.6 Cr As on 16 August, 2022 | 22:37

What is the P/E ratio of AstraZeneca Pharma India ?

The P/E ratio of AstraZeneca Pharma India is 106.8 As on 16 August, 2022 | 22:37

What is the PB ratio of AstraZeneca Pharma India ?

The PB ratio of AstraZeneca Pharma India is 14.9 As on 16 August, 2022 | 22:37

Q1FY23